Tissue distribution of polybutylcyanoacrylate nanoparticles carrying spin-labelled nitrosourea

doi:10.1016/0378-5173(88)90284-0

International Journal of Pharmaceutics

Volume 43, Issue 3, May 1988, Pages 267-271

https://doi.org/10.1016/0378-5173(88)90284-0 Get rights and content

Abstract

The opportunities and advantages of EPR spectroscopy for studying tissue distribution of polyalkylcyanoacrylate nanoparticles are discussed. Tissue distribution of polybutyl-2-cyanoacrylate nanoparticles (PBCN) having diameters of about 100 nm, charged by 1-(2-chloroethyl)-3-(1-oxy-2,2,6,6-tetra-methylpiperidinyl)-1-nitrosourea (spin-labelled nitrosourea, SLCNU) is investigated in C₅₇ Black mice, both healthy and tumor-bearing (subcutaneously implanted Melanom B16). PBCN modifies the tissue distribution profile of SLCNU; the kidney excretion rate is reduced to one third of normal; drug accumulation in the liver and in the brain is also reduced, and drug concentrations are lowered. An increased accumulation of SLCNU loaded PBCN in the tumor tissue is estimated.

References (14)

F. Brasseur et al.
Actinomycin D adsorbed on polymethylcyanoacrylate nanoparticles. Increased efficiency against an experimental tumor
Eur. J. Cancer
(1980)
P. Couvreur et al.
Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles
J. Pharm. Sci.
(1980)
P. Couvreur et al.
Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles
J. Pharm. Sci.
(1982)
B. Kante et al.
Tissue distribution of [³H]actinomycin D adsorbed on polybutylcyanoacrylates
Int. J. Pharm.
(1980)
J. Kreuter et al.
Polybutylcyanoacrylate nanoparticles for delivery of ⁷⁵Senorcholestenol
Int. J. Pharm.
(1983)
V. Lenaerts et al.
Degradation of poly(isobutyl cyanoacrylate) nanoparticles
Biomaterials
(1984)
V. Lenaerts et al.
In vivo uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Kupffer endothelial and parenchymal cells
J. Pharm. Sci.
(1984)

There are more references available in the full text version of this article.

Cited by (8)

Poly(alkyl cyanoacrylate) Nanoparticles as Promising Tools in Cancer Therapeutics
2019, Polymeric Nanoparticles as a Promising Tool for Anti-cancer Therapeutics
Delivery of peptide and protein drugs over the blood-brain barrier
2009, Progress in Neurobiology
Peptide and protein (P/P) drugs have been identified as showing great promises for the treatment of various neurodegenerative diseases. A major challenge in this regard, however, is the delivery of P/P drugs over the blood–brain barrier (BBB). Intense research over the last 25 years has enabled a better understanding of the cellular and molecular transport mechanisms at the BBB, and several strategies for enhanced P/P drug delivery over the BBB have been developed and tested in preclinical and clinical–experimental research. Among them, technology-based approaches (comprising functionalized nanocarriers and liposomes) and pharmacological strategies (such as the use of carrier systems and chimeric peptide technology) appear to be the most promising ones. This review combines a comprehensive overview on the current understanding of the transport mechanisms at the BBB with promising selected strategies published so far that can be applied to facilitate enhanced P/P drug delivery over the BBB.
Drug transport to brain with targeted nanoparticles
2005, NeuroRx
Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50–300 nm generally). They cannot freely diffuse through the blood-brain barrier (BBB) and require receptor-mediated transport through brain capillary endothelium to deliver their content into the brain parenchyma. Polysorbate 80-coated polybutylcyanoacrylate nanoparticles can deliver drugs to the brain by a still debated mechanism. Despite interesting results these nanoparticles have limitations, discussed in this review, that may preclude, or at least limit, their potential clinical applications. Long-circulating nanoparticles made of methoxypoly(ethylene glycol)- polylactide or poly(lactide-co-glycolide) (mPEG-PLA/PLGA) have a good safety profiles and provide drug-sustained release. The availability of functionalized PEG-PLA permits to prepare target-specific nanoparticles by conjugation of cell surface ligand. Using peptidomimetic antibodies to BBB transcytosis receptor, brain-targeted pegylated immunonanoparticles can now be synthesized that should make possible the delivery of entrapped actives into the brain parenchyma without inducing BBB permeability alteration. This review presents their general properties (structure, loading capacity, pharmacokinetics) and currently available methods for immunonanoparticle preparation.
Patents on brain permeable nanoparticles
2013, Recent Patents on CNS Drug Discovery
Immunonanosystems to CNS pathologies: State of the art
2012, Nanotechnology in Health Care
Comparative study for brain delivery of tacrine using polysorbate 80 - Coated poly(butylcyanoacrylate) and pegylated-poly(butylcyanoacrylate) nanoparticles
2009, International Journal of Nano and Biomaterials

View all citing articles on Scopus

View full text

Tissue distribution of polybutylcyanoacrylate nanoparticles carrying spin-labelled nitrosourea

Abstract

Eur. J. Cancer

J. Pharm. Sci.

J. Pharm. Sci.

Int. J. Pharm.

Int. J. Pharm.

Biomaterials

J. Pharm. Sci.